Literature DB >> 2516715

Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.

J A Leon1, R Mesa-Tejada, M C Gutierrez, A Estabrook, J W Greiner, J Schlom, P B Fisher.   

Abstract

In the present study we have evaluated the effect of recombinant interferons, including leukocyte (IFN-alpha A), fibroblast (IFN-beta) and immune (IFN-gamma), and the tumor promoting agent 12-0-tetradecanoyl-phorbol-13-acetate (TPA) on the expression of tumor associated antigens (TAA) and class II HLA-DR antigens on human breast carcinoma cell lines. The effect of these agents on the shedding of a high molecular weight tumor associated glycoprotein, BCA-225, was also determined. All three interferons and TPA enhanced the expression of the Mr 180,000 carcinoembryonic antigen (CEA) and CEA-related TAA recognized by monoclonal antibody B1.1 in both T47D and MCF-7 human breast carcinoma cell lines. The three types of interferons and TPA differed in their absolute TAA-augmenting ability, even in single-cell subclones derived from MCF-7 cells and previously shown to display a differential susceptibility to IFN-alpha augmentation of B1.1 expression. In general, IFN-gamma was more effective than IFN-alpha, IFN-beta or TPA in augmenting the expression of TAA, CEA and BCA-225, and HLA-DR expression in T47D and MCF-7 cells. Differences were also apparent in the ability of the three interferon preparations and TPA to induce shedding of BCA-225 in T47D and MCF-7 cells and their subclones. As observed with TAA expression, IFN-gamma was the most effective preparation in inducing TAA shedding. IFN-gamma also induced the expression and the shedding of BCA-225 by a subclone of T47D cells, T47D cl 17, which normally displays a reduced expression of BCA-225 and does not spontaneously shed this TAA without exposure to IFN-gamma. Recombinant leukocyte interferon (IFN-alpha A) also enhanced BCA-225 expression on T47D cells grown as xenografts in nude mice in vivo. The results of the present study emphasize the complexity of potential antigenic responses which can be induced in human breast carcinoma cells when they are exposed to biological response modulators, including different types of interferon, and tumor promoting agents, such as TPA. This investigation also indicates that both classes of agents can differentially augment expression and/or shedding of TAA by specific breast carcinoma cell lines as well as subclones derived from the same breast carcinoma cell line.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2516715

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Authors:  Megan C Duggan; Caroline Jochems; Renee N Donahue; Jacob Richards; Volodymyr Karpa; Elizabeth Foust; Bonnie Paul; Taylor Brooks; Susheela Tridandapani; Thomas Olencki; Xueliang Pan; Gregory B Lesinski; Jeffrey Schlom; William E Carson Iii
Journal:  Cancer Immunol Immunother       Date:  2016-08-31       Impact factor: 6.968

2.  Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons.

Authors:  G M Graham; L Guarini; T A Moulton; S Datta; S Ferrone; P Giacomini; R S Kerbel; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Characterization and functional analysis of the expression of intercellular adhesion molecule-1 in human papillomavirus-related disease of cervical keratinocytes.

Authors:  N Coleman; I M Greenfield; J Hare; H Kruger-Gray; B M Chain; M A Stanley
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

4.  Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons.

Authors:  J A Leon; M C Gutierrez; H Jiang; A Estabrook; S Waxman; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  The use of natural interferon alpha conjugated to a monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts.

Authors:  L Ozzello; C M De Rosa; E W Blank; K Cantell; R L Ceriani; D V Habif
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin.

Authors:  Joseph A Bauer; Bei H Morrison; Ronald W Grane; Barbara S Jacobs; Sally Dabney; Ana M Gamero; Kevin A Carnevale; Daniel J Smith; Judith Drazba; Bellur Seetharam; Daniel J Lindner
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

7.  In vitro differentiation and antigenic changes in human melanoma cell lines.

Authors:  L Guarini; M Temponi; G M Edwalds; J R Vita; P B Fisher; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  The melanoma differentiation associated gene mda-7 suppresses cancer cell growth.

Authors:  H Jiang; Z Z Su; J J Lin; N I Goldstein; C S Young; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.